ERBB2 and breast carcinoma: MONARCH-3 was a phase III randomized clinical trial that involved the enrollment of 493 HR-positive, HER2-negative breast cancer patients with advanced disease who have not received previous treatment and randomized to receive either abemaciclib plus anastrozole or letrozole or placebo plus anstrozole or letrozole [364].